Verona Pharma PLC (VRNA)
35.66
+0.29
(+0.82%)
USD |
NASDAQ |
Nov 15, 16:00
35.69
+0.03
(+0.08%)
After-Hours: 20:00
Verona Pharma Research and Development Expense (TTM): 40.83M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 40.83M |
| June 30, 2024 | 33.23M |
| March 31, 2024 | 11.37M |
| December 31, 2023 | 17.22M |
| September 30, 2023 | 19.93M |
| June 30, 2023 | 26.81M |
| March 31, 2023 | 44.27M |
| December 31, 2022 | 49.28M |
| September 30, 2022 | 65.15M |
| June 30, 2022 | 77.88M |
| March 31, 2022 | 83.46M |
| December 31, 2021 | 79.41M |
| September 30, 2021 | 72.94M |
| June 30, 2021 | 63.20M |
| March 31, 2021 | 50.45M |
| December 31, 2020 | 44.50M |
| Date | Value |
|---|---|
| September 30, 2020 | 35.47M |
| June 30, 2020 | 37.39M |
| March 31, 2020 | 42.15M |
| December 31, 2019 | 42.26M |
| September 30, 2019 | 41.74M |
| June 30, 2019 | 33.96M |
| March 31, 2019 | 26.47M |
| December 31, 2018 | 24.94M |
| September 30, 2018 | 31.50M |
| June 30, 2018 | 32.68M |
| March 31, 2018 | 33.90M |
| December 31, 2017 | 31.58M |
| September 30, 2017 | 20.44M |
| June 30, 2017 | 14.13M |
| March 31, 2017 | 8.528M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
11.37M
Minimum
Mar 2024
83.46M
Maximum
Mar 2022
46.86M
Average
43.26M
Median
Research and Development Expense (TTM) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| TC BioPharm (Holdings) PLC | -- |
| Adaptimmune Therapeutics PLC | 143.17M |
| NuCana PLC | 35.08M |
| Autolus Therapeutics PLC | 129.68M |